Location History:
- London, GB (1990)
- Stanford, CA (US) (1995)
Company Filing History:
Years Active: 1990-1995
Title: **Innovations by Inventor Michael Levitt from London**
Introduction
Michael Levitt, a prominent inventor based in London, GB, has made significant contributions to the field of biochemistry with a focus on enzyme technology. With a portfolio of two patents, Levitt's work exemplifies innovation in the development of subtilisin analogs. These analogs are particularly valuable in cleaning composition formulations due to their enhanced stability and efficacy.
Latest Patents
Levitt's latest patents revolve around the theme of modified subtilisins. The first patent, titled "Multiply Mutated Subtilisins," details a class of subtilisin analogs that are prepared by expressing a modified gene encoding the subtilisin analog in Bacillus subtilis. This patented technology boasts improved stability over naturally occurring Bacillus subtilisins, making it a robust ingredient for cleaning products. The second patent, simply referred to as "Subtilisin Analogs," also emphasizes similar advancements, describing the characteristics of these analogs as having a modified calcium binding site to enhance calcium binding, along with specific amino acid replacements to improve their performance in cleaning applications.
Career Highlights
Levitt is currently employed at Amgen Inc., a renowned biotechnology company known for its commitment to innovation in health care. His work at Amgen reflects the company's values and mission to develop breakthrough therapies. Levitt's dedication and foresight in enzyme technology have positioned him as a key player in the field.
Collaborations
Throughout his career, Levitt has had the opportunity to collaborate with notable professionals, including Mark M Zukowski and Yitzhak Stabinsky. These collaborations have further enriched his work and contributed to the success of his innovations, allowing for a diverse exchange of ideas and expertise.
Conclusion
In conclusion, Michael Levitt's contributions to enzyme technology through his innovative patents demonstrate his significant impact on the field. As he continues his work at Amgen Inc., the advancements in subtilisin analogs will likely play a critical role in enhancing the effectiveness of cleaning compositions, showcasing the potential of scientific research to drive practical applications in everyday products.